| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 2 | 3 | 3 | 6 | 6 | 12 | 12 | 11 | 15 | 15 | 18 | 21 |
| Expenses | 2 | 2 | 2 | 5 | 6 | 11 | 11 | 10 | 13 | 13 | 16 | 19 |
| EBITDA | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Operating Profit % | -12 % | -1 % | -19 % | -2 % | 7 % | 6 % | 1 % | -9 % | 4 % | 5 % | 3 % | 3 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 | -0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 2 | 0 | 0 | 1 |
| EPS in ₹ | 0.01 | 0.00 | 0.03 | 0.20 | 0.23 | 0.46 | 0.55 | -0.11 | 1.52 | 0.21 | 0.20 | 0.30 |
Veerhealth Care
Veerhealth Care
18.50
-0.13
(-0.70%)
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
38.20 Cr
EPS
0.20
PE Ratio
73.50
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
24.30
52 Week Low
9.29
PB Ratio
1.72
Debt to Equity
0.11
Sector
Pharmaceuticals Actual
Company News
View All News
Veerhealth Care Limited received an order worth Rs 0.81 crore from one of India's leading pharmacy chains for manufacturing and supplying hair care and oral care products. The customer operates over 5,000 retail pharmacy outlets, representing the largest retail pharmacy network in India. The domestic order must be executed within 20 days. The company expects this order to contribute significantly to its growth and turnover. The contract does not involve any related party transactions or promoter group interests.
Veerhealth Care Limited received new orders worth Rs 0.45 crores from a US customer for oral care products. The order involves 2 x 40 FT FCL containers for Drug OTC range products and must be executed within 30 days. The customer's identity remains undisclosed due to a Non-Disclosure Agreement. The company expects these orders to play a major role in boosting its export business in the US market. The transaction does not involve related party dealings or promoter group interests.
Veerhealth Care Reports 112.40% Revenue Growth to ₹5.14 Crore in Q1 FY26Aug 13, 2025
Veerhealth Care Limited reported total income of ₹5.14 crore for Q1 FY26, marking 112.40% year-over-year growth. EBITDA reached ₹0.62 crore with 82.35% growth and 12.06% margin. Net profit grew 104.08% to ₹0.24 crore with 4.67% margin. The company received USFDA clearance for drug exports to the USA and completed formalities for medical device exports. It secured regulatory approval from Gujarat's Food and Drug Authority for personal care manufacturing and received its first commercial order worth ₹0.48 crore. The company dispatched 3 export shipments to the US and received a ₹0.74 crore export order for oral care products. Ayuveer products were onboarded on Myntra, joining Amazon, Flipkart, Nykaa, Glowroad, and Jiomart. Production commenced at a new facility with in-house plastic molding capabilities. Managing Director Bhavin Shah expects total revenues of ₹30-35 crores with 10% PAT for FY 2025-26, and projects reaching ₹100 crores revenue with 10% PAT within 24-36 months.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,631.60 | #1 3,96,634.10 | 34.59 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 52.19 | |
6,120.50 | 1,62,055.30 | 67.06 | 9,712.00 | 18.67 | 2,191 | 26.74 | 56.39 | |
1,494.60 | 1,22,237.40 | 22.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.43 | |
3,569.00 | 1,19,704.80 | 59.08 | 11,539.40 | 6.99 | 1,911 | 19.91 | 49.24 | |
1,234.50 | 1,04,201.50 | #1 18.34 | 33,741.20 | 16.73 | 5,725 | 1.26 | 39.35 | |
2,454.90 | 1,02,393.00 | 53.53 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.95 | |
985.95 | 99,405.90 | 21.46 | 23,511.00 | 18.55 | 4,615 | 2.60 | 42.63 | |
1,905.60 | 87,916.10 | 23.93 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 40.58 | |
5,493.50 | 65,665.10 | 28.86 | 13,458.30 | 3.70 | 2,216 | 21.39 | 58.27 | |
29,925.00 | 63,376.00 | 43.95 | 6,684.70 | 9.64 | 1,414 | 11.55 | 38.74 |
Growth Rate
Revenue Growth
22.60 %
Net Income Growth
-
Cash Flow Change
-113.45 %
ROE
-5.38 %
ROCE
-49.90 %
EBITDA Margin (Avg.)
-31.41 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 14 | 14 | 13 | 15 | 16 | 18 | 19 | 20 | 25 | 28 | 34 |
| Fixed Assets | 2 | 3 | 3 | 6 | 6 | 10 | 10 | 11 | 12 | 12 | 20 |
| Current Assets | 8 | 7 | 8 | 7 | 3 | 6 | 7 | 6 | 10 | 14 | 11 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 12 | 11 | 11 | 9 | 9 | 9 | 9 | 10 | 13 | 16 | 14 |
| Total Liabilities | 14 | 14 | 13 | 15 | 16 | 18 | 19 | 20 | 25 | 28 | 34 |
| Current Liabilities | 1 | 1 | -0 | 1 | 3 | 2 | 2 | 3 | 1 | 3 | 4 |
| Non Current Liabilities | 1 | 1 | 1 | 0 | 0 | 3 | 3 | 4 | 3 | 4 | 8 |
| Total Equity | 13 | 13 | 13 | 13 | 13 | 14 | 14 | 14 | 21 | 22 | 22 |
| Reserve & Surplus | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 11 | 2 | 2 |
| Share Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 10 | 20 | 20 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 | 3 | -3 | 1 |
| Investing Activities | 4 | 0 | -0 | -3 | -2 | -2 | -0 | -1 | -2 | -0 | -8 |
| Operating Activities | -4 | 0 | 2 | 2 | 2 | -0 | 1 | 2 | -1 | 3 | -0 |
| Financing Activities | 0 | 0 | -1 | 1 | 0 | 2 | -1 | -0 | 6 | -6 | 10 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 41.92 % | 41.92 % | 41.93 % | 41.93 % | 42.34 % | 44.31 % | 44.36 % | 44.36 % | 30.76 % | 30.76 % | 30.76 % | 30.76 % | 30.41 % | 30.41 % | 30.41 % | 30.41 % | 31.50 % | 31.50 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 48.78 % | 48.53 % | 48.11 % | 47.50 % | 47.42 % | 44.95 % | 37.12 % | 47.81 % | 55.14 % | 58.28 % | 56.23 % | 56.80 % | 60.05 % | 59.25 % | 58.57 % | 58.53 % | 58.35 % | 57.92 % |
| Others | 9.29 % | 9.55 % | 9.96 % | 10.57 % | 10.24 % | 10.73 % | 18.52 % | 7.83 % | 14.10 % | 10.96 % | 13.01 % | 12.44 % | 9.54 % | 10.33 % | 11.02 % | 11.06 % | 10.15 % | 10.58 % |
| No of Share Holders | 3,528 | 3,517 | 3,483 | 3,462 | 3,642 | 3,566 | 3,589 | 3,655 | 3,605 | 3,616 | 6,195 | 6,874 | 10,991 | 10,255 | 11,489 | 11,469 | 11,390 | 11,011 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 22 Sept 2023 |  Bonus | 1:1 | 22 Sept 2023 | 40.72 | 41.24 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 22.37 | 22.09 |
| 14 Nov 2024 |  Quarterly Result Announcement | NA | 14 Nov 2024 | 19.97 | 18.24 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 18.51 | 17.21 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 13.19 | 15.21 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 22.13 | 21.94 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 21.94 | 18.02 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order7 days ago
7 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report7 days ago
7 days agoShareholder Meeting / Postal Ballot-Outcome of AGM8 days ago
8 days agoClosure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderSep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 05, 2025
Sep 05, 2025Reg. 34 (1) Annual Report.Aug 22, 2025
Aug 22, 2025Shareholder Meeting - AGM On September 30 2025Aug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Aug 13, 2025Results-Financial Results For June 30 2025Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 04, 2025
Aug 04, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2025.Aug 01, 2025
Aug 01, 2025UpdatesJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 09, 2025
Jul 09, 2025Announcement Under Regulation 30 (LODR) - Contract Manufacturing Agreement With Leading Marketplace CompanyJul 07, 2025
Jul 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Jul 04, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 17, 2025
Jun 17, 2025Announcement Under Regulation 30 (LODR) - "Ayuveer" Products Now Available On Myntra For PurchaseJun 16, 2025
Jun 16, 2025Announcement Under Regulation 30 (LODR) - Appointment Of Internal And Secretarial AuditorMay 30, 2025
May 30, 2025Results-Financial Results For March 31 2025May 30, 2025
May 30, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
May 22, 2025Board Meeting Intimation for Consideration And Approval Of Audited Financial Results Of The Company For The Quarter And Financial Year Ended 31St March 2025 And Recommendation Of Dividend If Any.May 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
May 20, 2025Announcement Under Regulation 30 (LODR) - Successful Closure Of USFDA Inspection Under 21 CFR 20.64(D)(3)May 16, 2025
May 16, 2025Compliances-Compliance Certificate For The Period Ended March 31 2025Apr 04, 2025
Apr 04, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2025
Apr 04, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 07, 2025
Mar 07, 2025Integrated Filing (Financial)Feb 12, 2025
Feb 12, 2025Results-Financial Results For December 31 2024Feb 12, 2025
Feb 12, 2025Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2025
Feb 12, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 2024Feb 04, 2025
Feb 04, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Jan 06, 2025Closure of Trading WindowDec 28, 2024
Dec 28, 2024Announcement Under Regulation 30 (LODR) - Introduction Of New Division In Hospital Care SegmentDec 18, 2024
Dec 18, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 14, 2024
Dec 14, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 12, 2024
Dec 12, 2024Announcement Under Regulation 30 (LODR) - Closure Of Assessment By USFDA Of Form 4003 - FDA Pre-Inspection Records RequestDec 11, 2024
Dec 11, 2024Technical Indicators
RSI(14)
Neutral 46.41
ATR(14)
Less Volatile 0.88
STOCH(9,6)
Neutral 58.39
STOCH RSI(14)
Overbought 91.53
MACD(12,26)
Bullish 0.18
ADX(14)
Weak Trend 12.24
UO(9)
Bearish 54.41
ROC(12)
Uptrend And Accelerating 3.21
WillR(14)
Neutral -43.50
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
